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Assessing the credibility of findings from non-randomised studies of 
interventions 
Randomised controlled trials (RCTs) are widely accepted as the gold standard in 
assessment of health interventions. However, evidence from RCTs is often unavailable. 
They may be impractical, for example when the outcome of interest is so rare, or long-term, 
that appropriately-sized studies would be too expensive. RCTs require clinical equipoise, 
and withholding established treatments may be considered unethical even if evidence for 
their effects is limited. Or, RCTs may be underway but not due to report for some years. 
In such situations, evidence from non-randomised studies of interventions, such as cohort 
studies and case-control studies, can be essential in assessing the effects of an intervention. 
Moreover, the increasing availability of large electronic health record datasets is leading to 
unprecedented opportunities to compare the effects of healthcare interventions being used 
in routine practice. For example, a recent study published in this journal examined the 
effects of multiple arterial grafting versus standard treatment on rare safety events and long-
term benefit. RCTs are often unable to examine rare and long-term outcomes, and so data 
on over 20000 patients from the Cardiac Services British Columbia registry were analysed.1  
Observational studies have inherent limitations, including biases due to confounding (when 
prognostic factors affect the intervention received), participant selection, missing data (on 
confounders or outcomes), and outcome measurement error. Because such biases may be 
unfamiliar or hard to identify, it is essential to adopt a structured approach when considering 
the extent to which they are present when evaluating evidence from non-randomised 
studies. 
Formal evaluations of risk of bias are frequently undertaken in the context of a systematic 
review, although they are sometimes undertaken for other purposes. Numerous tools have 
been developed for assessing the methodological quality of observational studies. One of 
the best and most commonly used is the Newcastle-Ottawa Scale,2 although this overlooks 
some important sources of bias. Our team recently proposed a new tool, the Risk Of Bias In 
Non-randomised Studies of Interventions (ROBINS-I) tool, based on modern ideas of causal 
inference in epidemiology.3 Developed through expert consensus and extensive piloting, 
ROBINS-I follows a recent shift in focus from research quality to risk of bias and directly 
addresses a study’s internal validity.  
ROBINS-I considers each non-randomised study as an attempt to mimic a ‘target trial’, 
defined as a large, pragmatic, randomised trial that assesses the effect of the same 
intervention in the same population, but which does not have factors putting it at risk of bias. 
Bias is then defined as the non-randomised study’s tendency to produce results that differ 
systematically from those produced by the target trial. The hypothetical target trial does not 
need to be feasible or ethical: for example, it might involve randomisation of patients to 
intensive care versus a bed on a standard ward. 
Based on the target trial and the effect of interest, ROBINS-I assesses the potential for bias 
to be introduced into a study’s result across seven bias domains. The first, and most widely 
appreciated, is bias due to confounding, which arises from differences in the distribution of 
prognostic factors between intervention groups at the start of intervention. This is the main 
bias that randomisation seeks to overcome. For example a review of randomised and non-
randomised studies of intra-aortic balloon pump therapy for acute myocardial infarction 
found little evidence of benefit in the randomised trials but substantial variation between 
results of non-randomised studies.4 Much of this variation seemed to be explained by 
differences between characteristics of intervention groups at baseline, suggesting that 
confounding was introducing bias. 
The second domain is bias in selection of participants into the study, which considers the 
extent to which the association between intervention and outcome may have been distorted 
due to selecting participants based on events occurring after the start of intervention. The 
third is bias in classification of interventions, which includes consideration of whether 
information about intervention status might have been affected by subsequent outcomes 
(including the well-known problem of ‘recall bias’ in case-control studies). 
The remaining domains relate to biases that can also affect results of randomised trials. The 
fourth is bias due to deviations from intended interventions, which is particularly important 
when interest focusses on the effect of adherence to intervention (for which deviations 
clearly introduce problems). The fifth is bias due to missing data, and the sixth is bias in 
measurement of outcomes. The last domain, bias in the selection of the reported results, 
tackles the rather different problem of authors presenting only the most exciting (or 
statistically significant) findings. 
Within each domain, ROBINS-I poses a series of broadly factual questions (‘signalling 
questions’) about what happened in the study, the answers to which directly inform a risk-of-
bias judgement for that domain. In turn, the domain-level judgements inform an overall 
judgement (of ‘low’, ‘moderate’, ‘serious’ or ‘critical’ risk of bias) for the result in question. 
Specifying a target trial can help reveal important biases in non-randomised studies that may 
not be immediately apparent. For example, consider the well-known erroneous finding from 
the Nurses’ Health observational cohort study that hormone replacement therapy (HRT) is 
associated with an approximate halving of cardiovascular risk.5 A hypothetical trial of HRT 
would randomise eligible women not currently taking HRT to start either HRT or placebo. In 
contrast, the Nurses’ Health Study analysis included women who had started taking HRT 
before follow-up began, leading to selection bias. Re-analysis of the Nurses’ Health Study 
using an approach that mimicked a randomised trial produced results similar to that from a 
large trial.6 On the other hand, in an analysis of primary care electronic medical records that 
mimicked a target trial of statins and antihypertensives compared with no treatment, 
unmeasured confounding was a likely explanation for underestimation of the benefit of 
treatment.7 
Specifying a target trial requires articulation of the population of interest, the experimental 
and comparator interventions, and the outcome(s) of interest. This creates a need for 
interdisciplinary collaboration: input from both methodological and subject-specific experts is 
necessary to define the target trial and identify the participant characteristics that might 
introduce confounding. The ROBINS-I tool also requires a decision as to whether interest 
focusses on the effect of being assigned to an intervention (often termed the ‘intention-to-
treat’ effect) or the effect of adhering to the assigned intervention (often termed the ‘per-
protocol’ effect) and assesses risk of bias in relation to the chosen effect of interest.  
Due to the assessment’s foundation in a target randomised trial, a rating of low risk of bias 
would mean that the results may be regarded as equivalent to those from a high quality 
randomised trial. Because it is usually impossible to exclude residual or unmeasured 
confounding, we expect most results from non-randomised studies to be assessed at best as 
at moderate risk of bias. A rating of critical risk of bias implies that the result should not be 
included in any quantitative evidence synthesis. 
The ROBINS-I tool is being adopted widely, including by Cochrane and the GRADE Working 
Group.8 We expect its uptake within the context of systematic reviews and meta-analyses to 
increase substantially, helping to avoid review authors over-interpreting findings from non-
randomised evidence, and facilitating explanations of discrepancies between findings from 
randomised and non-randomised studies. We also hope that the tool offers a useful 
framework for funders, peer reviewers and readers of journals such as JAMA Cardiology to 
think through the extent to which findings from a non-randomised study are credible. 
 
Resources 
The ROBINS-I tool, along with details of the development team and extensive guidance, is 
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